Literature DB >> 29299649

Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Peri-Operative Outcomes.

Fabio Bagante1, Gaya Spolverato1, Matthew Weiss2, Sorin Alexandrescu3, Hugo P Marques4, Luca Aldrighetti5, Shishir K Maithel6, Carlo Pulitano7, Todd W Bauer8, Feng Shen9, George A Poultsides10, Olivier Soubrane11, Guillaume Martel12, B Groot Koerkamp13, Alfredo Guglielmi1, Endo Itaru14, Andrea Ruzzenente1, Timothy M Pawlik15.   

Abstract

BACKGROUND: The consequences of lymphadenectomy (LND) on cirrhotic patients undergoing hepatectomy for intrahepatic cholangiocarcinoma (ICC) have not been investigated. We sought to analyze the impact of LND on morbidity among patients undergoing resection for ICC.
METHODS: A total of 1005 patients who underwent hepatectomy for ICC at one of the 14 participating institutions between 1990 and 2015 were identified. A propensity score match analysis was performed to reduce confounding biases between cirrhosis and non-cirrhosis groups.
RESULTS: Cirrhosis was diagnosed in 118 (11.7%) patients. Among non-cirrhotic patients, 63% underwent major liver resection versus only 20% among patients with cirrhosis (p < 0.001). LND was also less common among cirrhotic versus non-cirrhotic patients (19 vs. 50%, p < 0.001). The incidence of complications was 41 and 30% among patients who did not and did have cirrhosis, respectively (p = 0.022). The propensity-matched cohort included 150 patients. The incidence of complications was 71% among patients who underwent lymphadenectomy versus 23% among patients who did not undergo lymphadenectomy (OR 8.39) (p < 0.001). In the propensity-matched analysis, the median HLN was comparable among patients independent of cirrhosis status (median HLN: non-cirrhosis, 2.5 vs. cirrhosis, 2) (p = 0.95). While lymphadenectomy was associated with a higher risk of infections (non-cirrhosis, 0% vs. cirrhosis, 21%, p < 0.001) among patients with cirrhosis, infections were not associated with lymphadenectomy among non-cirrhotic patients (p = 0.19).
CONCLUSION: Lymphadenectomy was associated with an increased risk of complications among patients with cirrhosis undergoing surgery for ICC. The benefit of lymphadenectomy in cirrhotic patients should be considered in light of the higher risk of postoperative complications compared with non-cirrhotic patients.

Entities:  

Mesh:

Year:  2018        PMID: 29299649     DOI: 10.1007/s00268-017-4453-1

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


  30 in total

1.  A comparison of the ability of different propensity score models to balance measured variables between treated and untreated subjects: a Monte Carlo study.

Authors:  Peter C Austin; Paul Grootendorst; Geoffrey M Anderson
Journal:  Stat Med       Date:  2007-02-20       Impact factor: 2.373

Review 2.  Metabolic syndrome and non-alcoholic fatty liver disease in liver surgery: The new scourges?

Authors:  François Cauchy; David Fuks; Alban Zarzavadjian Le Bian; Jacques Belghiti; Renato Costi
Journal:  World J Hepatol       Date:  2014-05-27

Review 3.  Clinical presentation, risk factors and staging systems of cholangiocarcinoma.

Authors:  Ruben R Plentz; Nisar P Malek
Journal:  Best Pract Res Clin Gastroenterol       Date:  2015-02-14       Impact factor: 3.043

4.  Evaluation of the 8th edition American Joint Commission on Cancer (AJCC) staging system for patients with intrahepatic cholangiocarcinoma: A surveillance, epidemiology, and end results (SEER) analysis.

Authors:  Yuhree Kim; Dimitrios P Moris; Xu-Feng Zhang; Fabio Bagante; Gaya Spolverato; Carl Schmidt; Mary Dilhoff; Timothy M Pawlik
Journal:  J Surg Oncol       Date:  2017-06-12       Impact factor: 3.454

Review 5.  Epidemiology of cholangiocarcinoma: an update focusing on risk factors.

Authors:  Hai-Rim Shin; Jin-Kyoung Oh; Eric Masuyer; Maria-Paula Curado; Veronique Bouvard; Yue-Yi Fang; Surapon Wiangnon; Banchob Sripa; Sung-Tae Hong
Journal:  Cancer Sci       Date:  2009-12-04       Impact factor: 6.716

Review 6.  Liver surgery in cirrhosis and portal hypertension.

Authors:  Christina Hackl; Hans J Schlitt; Philipp Renner; Sven A Lang
Journal:  World J Gastroenterol       Date:  2016-03-07       Impact factor: 5.742

Review 7.  Intrahepatic cholangiocarcinoma: Epidemiology, risk factors, diagnosis and surgical management.

Authors:  Han Zhang; Tian Yang; Mengchao Wu; Feng Shen
Journal:  Cancer Lett       Date:  2015-09-25       Impact factor: 8.679

8.  Risk factors for intrahepatic and extrahepatic cholangiocarcinoma in the United States: a population-based case-control study.

Authors:  Tania M Welzel; Barry I Graubard; Hashem B El-Serag; Yasser H Shaib; Ann W Hsing; Jessica A Davila; Katherine A McGlynn
Journal:  Clin Gastroenterol Hepatol       Date:  2007-08-06       Impact factor: 11.382

Review 9.  Cholangiocarcinoma: New Insights

Authors:  Vedat Goral
Journal:  Asian Pac J Cancer Prev       Date:  2017-06-25

10.  Risk stratification system to predict recurrence of intrahepatic cholangiocarcinoma after hepatic resection.

Authors:  Seogsong Jeong; Qingbao Cheng; Lifeng Huang; Jian Wang; Meng Sha; Ying Tong; Lei Xia; Longzhi Han; Zhifeng Xi; Jianjun Zhang; Xiaoni Kong; Jinyang Gu; Qiang Xia
Journal:  BMC Cancer       Date:  2017-07-03       Impact factor: 4.430

View more
  10 in total

Review 1.  [Surgical treatment of hepatic tumors-liver resection and transplantation].

Authors:  H Lang; S Heinrich; F Bartsch; F Hüttl; J Baumgart; J Mittler
Journal:  Internist (Berl)       Date:  2020-02       Impact factor: 0.743

Review 2.  [Cholangiocarcinoma-Intrahepatic to hilar bile duct cancer].

Authors:  Sebastian Rademacher; Timm Denecke; Thomas Berg; Daniel Seehofer
Journal:  Chirurgie (Heidelb)       Date:  2022-06-13

Review 3.  Neoadjuvant and Adjuvant Therapy in Intrahepatic Cholangiocarcinoma.

Authors:  Xing Chen; Jinpeng Du; Jiwei Huang; Yong Zeng; Kefei Yuan
Journal:  J Clin Transl Hepatol       Date:  2022-01-04

4.  Liver Cancer Study Group of Japan Clinical Practice Guidelines for Intrahepatic Cholangiocarcinoma.

Authors:  Shoji Kubo; Hiroji Shinkawa; Yoshinari Asaoka; Tatsuya Ioka; Hiroshi Igaki; Namiki Izumi; Takao Itoi; Michiaki Unno; Masayuki Ohtsuka; Takuji Okusaka; Masumi Kadoya; Masatoshi Kudo; Takashi Kumada; Norihiro Kokudo; Michiie Sakamoto; Yoshihiro Sakamoto; Hideyuki Sakurai; Tadatoshi Takayama; Osamu Nakashima; Yasushi Nagata; Etsuro Hatano; Kenichi Harada; Takamichi Murakami; Masakazu Yamamoto
Journal:  Liver Cancer       Date:  2022-02-23       Impact factor: 12.430

5.  Prognostic Value of Lymph Node Dissection for Intrahepatic Cholangiocarcinoma Patients With Clinically Negative Lymph Node Metastasis: A Multi-Center Study From China.

Authors:  Qiao Ke; Lei Wang; Ziguo Lin; Jianying Lou; Shuguo Zheng; Xinyu Bi; Jianming Wang; Wei Guo; Fuyu Li; Jian Wang; Yamin Zheng; Jingdong Li; Shi Cheng; Weiping Zhou; Yongyi Zeng
Journal:  Front Oncol       Date:  2021-03-11       Impact factor: 6.244

Review 6.  Resection for intrahepatic cholangiocellular cancer: new advances.

Authors:  Daniel R Waisberg; Rafael S Pinheiro; Lucas S Nacif; Vinicius Rocha-Santos; Rodrigo B Martino; Rubens M Arantes; Liliana Ducatti; Quirino Lai; Wellington Andraus; Luiz C D'Albuquerque
Journal:  Transl Gastroenterol Hepatol       Date:  2018-09-12

7.  Minimally invasive surgical treatment of intrahepatic cholangiocarcinoma: A systematic review.

Authors:  Renato Patrone; Francesco Izzo; Raffaele Palaia; Vincenza Granata; Guglielmo Nasti; Alessandro Ottaiano; Gilda Pasta; Andrea Belli
Journal:  World J Gastrointest Oncol       Date:  2021-12-15

Review 8.  Combined Hepatocellular-Cholangiocarcinoma: What the Multidisciplinary Team Should Know.

Authors:  Carmen Cutolo; Federica Dell'Aversana; Roberta Fusco; Giulia Grazzini; Giuditta Chiti; Igino Simonetti; Federico Bruno; Pierpaolo Palumbo; Luca Pierpaoli; Tommaso Valeri; Francesco Izzo; Andrea Giovagnoni; Roberto Grassi; Vittorio Miele; Antonio Barile; Vincenza Granata
Journal:  Diagnostics (Basel)       Date:  2022-04-02

9.  Impact of cirrhosis on long-term survival outcomes of patients with intrahepatic cholangiocarcinoma.

Authors:  Jian Wang; Yiwen Qiu; Yi Yang; Shu Shen; Ming Zhi; Bo Zhang; Wentao Wang
Journal:  Cancer Med       Date:  2022-04-12       Impact factor: 4.711

Review 10.  The new insight of treatment in Cholangiocarcinoma.

Authors:  Yuhang Li; Yinghui Song; Sulai Liu
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.